Stefanie Grabrucker

Background: Ageing is frequently associated with systemic inflammation and cognitive decline, yet the impact of diet and lifestyle factors on these age-related processes remains unexplored. Nutrient deficiencies, particularly in essential vitamins and minerals, may accelerate cognitive decline and heighten inflammation in older adults. Aim: This pilot study aimed to examine how dietary intake, body mass index (BMI) and physical activity affect plasma cytokine levels and cognitive performance in older adults. Methods: Twenty-nine healthy Irish adults, aged 65–85 years participated in the study. Physical examination, cognitive testing using the Cambridge Neuropsychological Test Automated Battery and plasma cytokine analysis (tumor necrosis factor-alpha [TNF-α], interleukin [IL]-6, IL-10, IL-8, IL-4, IL-1β) were conducted. Dietary intake was assessed using a validated Food Frequency Questionnaire, and physical activity was evaluated using the International Physical Activity Questionnaire. Summary: Participants with higher BMI and lower physical activity levels exhibited increased plasma concentrations of TNF-α, indicating elevated systemic inflammation and altered IL-10 levels, reflecting changes in anti-inflammatory regulation. Cognitive performance was poorer in participants who consumed excessive carbohydrates and polyunsaturated fatty acids and also in those whose total caloric intake fell below European Food Safety Authority dietary reference values. In contrast, participants with higher intake of saturated and monounsaturated fatty acids demonstrated better cognitive function. Deficiencies in vitamin B12, magnesium, manganese and copper were linked to elevated inflammatory markers and poorer cognitive outcomes. Conclusion: This study highlights the importance of nutrition and lifestyle in managing inflammation and cognitive decline in ageing. Targeted dietary interventions which address nutrient deficiencies may help preserve cognitive health and reduce inflammation in older adults.

An international expert panel convened to evaluate nutrition-based approaches to brain health and dementia prevention. This consensus statement integrates perspectives from lived experiences, mechanistic evidence, epidemiology, and clinical interventions. Nutrition plays a crucial role in brain health throughout life and in cognitive decline pathogenesis, particularly through the food-gut-brain axis. Intervention effectiveness varies across the health promotion, prevention, treatment, and maintenance spectrum due to methodological differences and individual responses to nutritional interventions. The Mediterranean and MIND dietary patterns show promise for maintaining cognitive function across studies. Multi-domain interventions like FINGER effectively combine dietary modifications with lifestyle changes to delay dementia onset in at-risk older adults. These findings align with mechanistic evidence on the food-gut-brain axis in maintaining optimal brain health by preventing neurodegeneration. Key mechanisms include gut microbiota composition and function, blood-brain barrier integrity, endothelial and mitochondrial dysfunction, insulin resistance, oxidative stress, and inflammatory processes. Research priorities include standardizing cognitive assessment methodologies, developing early intervention strategies, and implementing integrated precision nutrition and lifestyle approaches. Incorporating patients’ and caregivers’ lived experiences in research co-production was identified as essential to support those with lived experience. The panel concluded that future directions should combine population and individual-level preventive approaches while addressing challenges in sustaining healthy behavioral changes and understanding the complex interplay between diet, lifestyle, and genetic factors in brain health and dementia prevention. Experts emphasized the need for both standardized methodologies and personalized interventions to account for individual variability in nutritional responses and facilitate effective prevention strategies across diverse populations.

Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRDs) are broad-impact multifactorial neurodegenerative diseases. Their complexity presents unique challenges for developing effective therapies. This review highlights research presented at the 2024 Society for Neuroscience meeting which emphasized the gut microbiome's role in AD pathogenesis by influencing brain function and neurodegeneration through the microbiota–gut–brain axis. This emerging evidence underscores the potential for targeting the gut microbiota to treat AD/ADRD.

Alzheimer’s disease is a complex neurodegenerative disorder leading to a decline in cognitive function and mental health. Recent research has positioned the gut microbiota as an important susceptibility factor in Alzheimer’s disease by showing specific alterations in the gut microbiome composition of Alzheimer’s patients and in rodent models. However, it is unknown whether gut microbiota alterations are causal in the manifestation of Alzheimer’s symptoms. To understand the involvement of Alzheimer’s patient gut microbiota in host physiology and behaviour, we transplanted faecal microbiota from Alzheimer’s patients and age-matched healthy controls into microbiota-depleted young adult rats. We found impairments in behaviours reliant on adult hippocampal neurogenesis, an essential process for certain memory functions and mood, resulting from Alzheimer’s patient transplants. Notably, the severity of impairments correlated with clinical cognitive scores in donor patients. Discrete changes in the rat caecal and hippocampal metabolome were also evident. As hippocampal neurogenesis cannot be measured in living humans but is modulated by the circulatory systemic environment, we assessed the impact of the Alzheimer’s systemic environment on proxy neurogenesis readouts. Serum from Alzheimer’s patients decreased neurogenesis in human cells in vitro and were associated with cognitive scores and key microbial genera. Our findings reveal for the first time, that Alzheimer’s symptoms can be transferred to a healthy young organism via the gut microbiota, confirming a causal role of gut microbiota in Alzheimer’s disease, and highlight hippocampal neurogenesis as a converging central cellular process regulating systemic circulatory and gut-mediated factors in Alzheimer’s.

Background: Autism Spectrum Disorders (ASD) patients experience disturbed nociception in the form of either hyposensitivity to pain or allodynia. A substantial amount of processing of somatosensory and nociceptive stimulus takes place in the dorsal spinal cord. However, many of these circuits are not very well understood in the context of nociceptive processing in ASD.Methods: We have used a Shank2^−/−mouse model, which displays a set of phenotypes reminiscent of ASD, and performed behavioural and microscopic analysis to investigate the role of dorsal horn circuitry in nociceptive processing of ASD.Results: We determined that Shank2^−/−mice display increased sensitivity to formalin pain and thermal preference, but a sensory specific mechanical allodynia. We demonstrate that high levels of Shank2 expression identifies a subpopulation of neurons in murine and human dorsal spinal cord, composed mainly by glycinergic interneurons and that loss of Shank2 causes the decrease in NMDAR in excitatory synapses on these inhibitory interneurons. In fact, in the subacute phase of the formalin test, glycinergic interneurons are strongly activated in wild type (WT) mice but not in Shank2^−/−mice. Consequently, nociception projection neurons in laminae I are activated in larger numbers in Shank2^−/−mice.Limitations: Our investigation is limited to male mice, in agreement with the higher representation of ASD in males; therefore, caution should be applied to extrapolate the findings to females. Furthermore, ASD is characterized by extensive genetic diversity and therefore the findings related to Shank2 mutant mice may not necessarily apply to patients with different gene mutations. Since nociceptive phenotypes in ASD range between hyper- and hypo-sensitivity, diverse mutations may affect the circuit in opposite ways.Conclusion: Our findings prove that Shank2 expression identifies a new subset of inhibitory interneurons involved in reducing the transmission of nociceptive stimuli and whose unchecked activation is associated with pain hypersensitivity. We provide evidence that dysfunction in spinal cord pain processing may contribute to the nociceptive phenotypes in ASD.

Members of the Shank protein family are master scaffolds of the postsynaptic architecture and mutations within the SHANK genes are causally associated with autism spectrum disorders (ASDs). We generated a Shank2-Shank3 double knockout mouse that is showing severe autism related core symptoms, as well as a broad spectrum of comorbidities. We exploited this animal model to identify cortical brain areas linked to specific autistic traits by locally deleting Shank2 and Shank3 simultaneously. Our screening of 10 cortical subregions revealed that a Shank2/3 deletion within the retrosplenial area severely impairs social memory, a core symptom of ASD. Notably, DREADD-mediated neuronal activation could rescue the social impairment triggered by Shank2/3 depletion. Data indicate that the retrosplenial area has to be added to the list of defined brain regions that contribute to the spectrum of behavioural alterations seen in ASDs.

Middle age is increasingly accepted as a key period during which individuals are susceptible to the effect of environmental and lifestyle factors. Emerging research indicates that dietary factors play a crucial role in brain health and cognitive function, and studies in both animals and humans have demonstrated that dietary interventions can mitigate cognitive impairment. Specifically, magnesium has been shown to enhance learning and memory, and magnesium deficiency is associated with impaired hippocampal-dependent memory formation in animal studies. The aim of this study was to examine if supplementation with a magnesium-rich marine mineral blend (MMB) could alter middle-age-related cognitive impairment. Young and middle-aged rats were given access to a control diet or an experimental diet formulated with an MMB for 4 weeks before undergoing a series of behavioral assessments. Supplementation of MMB to middle-aged rats rescued a deficit in cognitive impairment, specifically a pattern separation paradigm that is sensitive to alterations in a type of brain plasticity called neurogenesis. It had no effect on general activity in the open field or performance on other hippocampal-associated tasks. Changes in cognitive function occur as a predictable consequence of aging. Research into whether modification of dietary factors, such as this MMB, may play a role in the prevention of age-related cognitive impairment warrants further investigation.

EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

Older patients with severe physical trauma are at high risk of developing neuropsychiatric syndromes with global impairment of cognition, attention, and consciousness. We employed a thoracic trauma (TxT) mouse model and thoroughly analyzed age-dependent spatial and temporal posttraumatic alterations in the central nervous system. Up to 5 days after trauma, we observed a transient 50% decrease in the number of excitatory synapses specifically in hippocampal pyramidal neurons accompanied by alterations in attention and motor activity and disruption of contextual memory consolidation. In parallel, hippocampal corticotropin-releasing hormone (CRH) expression was highly upregulated, and brain-derived neurotrophic factor (BDNF) levels were significantly reduced. In vitro experiments revealed that CRH application induced neuronal autophagy with rapid lysosomal degradation of BDNF via the NF-κB pathway. The subsequent synaptic loss was rescued by BDNF as well as by specific NF-κB and CRH receptor 1 (CRHR1) antagonists. In vivo, the chronic application of a CRHR1 antagonist after TxT resulted in reversal of the observed histological, molecular, and behavioral alterations. The data suggest that neuropsychiatric syndromes (i.e., delirium) after peripheral trauma might be at least in part due to the activation of the hippocampal CRH/NF-κB/BDNF pathway, which results in a dramatic loss of synaptic contacts. The successful rescue by stress hormone receptor antagonists should encourage clinical trials focusing on trauma-induced delirium and/or other posttraumatic syndromes.

The accumulation of amyloid β (Aβ) triggers a cascade of toxic events in Alzheimer’s disease (AD). The KLVFF peptide can interfere with Aβ aggregation. However, the peptide suffers from poor bioavailability and the inability to cross the blood–brain barrier. In this work, we study the possibility of adopting nanomedicine to overcome KLVFF limits in biodistribution. We produced new engineered polymeric nanoparticles (NPs), and we evaluated the cellular toxicity of these NPs and validated that KVLFF peptides released by NPs show the same promising effects on AD pathology. Our results revealed the successful generation of KVLFF loaded NPs that, without significant effects on cell heath, are even more potent in reversing Aβ-induced pathologies compared to the free peptide. Therefore, NPs will significantly advance KVLFF treatment as a therapeutic option for AD.